Actions and Detail Panel
Opportunities and Challenges with Emerging Biomarker Technologies and their...
Mon 20 March 2017, 09:00 – 17:30 GMT
Opportunities and Challenges with Emerging Biomarker Technologies and their Application in Early Phase Trials
The ECMC Quality Assurance and Translational Science (QATS) Network's 'Translation Science Conference' will take place on 20 March 2017 at the Institute of Cancer Research in Sutton.
The conference will examine the theme “Opportunities and challenges with emerging biomarker technologies and their application in early phase trials”.
The conference is an opportunity to network with other QATS members and to hear about novel technologies being used for translational science across the network. Deadline for registration is Monday 6th March 2017.
Submit an abstract
Deadline 14th February 2017
We would like to encourage each ECMC to submit at least one abstract so the translational work across the ECMC can be showcased.
Abstracts should be no longer than 400 words and should demonstrate the validation or application of novel translational science / technologies in phase I clinical trials. Some abstracts will be selected to be presented as oral presentations in the ECMC Translational Science Breaking News session. The remainder will be put forward for poster presentations.
Abstracts should be in the following format:
Word document format (no PDFs)
Name of the authors with presenting author underlined and affiliations
Abstract text, formatted as a single section (400 word limit, no figures)
Indicate in the file if you would like to be considered for an oral presentation
Please email abstracts to firstname.lastname@example.org
09.00 Welcome and Introduction
09.10 – 10.10 ECMC Translational Science Breaking News
Featuring speakers selected from submitted abstracts
09.10 – 09.30 To be announced
09.30 - 09.50 To be announced
09.50 -10.10 To be announced
10.10 – 10.30 NCRI Cellular & Molecular Pathology Initiative (CM-Path): developing pathology research in clinical trials: Professor Gareth Thomas (Professor of Experimental Pathology, University of Southampton)
10.30 – 11.00 Coffee break, posters and exhibitors
11.00 – 11.45 Working in collaboration with a trial sponsor; successes, challenges and opportunities, Dr Sidath Katugampola & Dr Stephanie Traub (Biomarker Development Scientists, CDD, CRUK)
11.45 – 12.05 Mass cytometry in clinical settings, Dr Susanne Heck (Head of Flow Cytometry Research Platform, Guy’s and St Thomas’ NHS Foundation Trust and Kings College London)
12.05 – 12.25 Digital pathology and multispectral immunofluorescence
approaches to dissect the tumour microenvironment: Professor Benjamin Willcox (Professor of Molecular Immunology, Birmingham CRUK Cancer Centre Institute of Immunology and Immunotherapy) and Chris Bagnell (Queen Elizabeth
Hospital Charity Cancer Immunotherapeutics Support Officer)
12.25 – 13.25 Lunch, posters and exhibitors
13.25 – 14.10 NanoString Multiplexed Assays for Precision Oncology with extension to high-plex digital spatial profiling for Immuno-Oncology, Joseph M. Beecham PhD (Senior Vice President of Research and Development, Nanostring)
14.10 – 14.30 Analytical reproducibility & longitudinal stability of endogenous small molecules in biofluids: implications for use as biomarkers, Dr Hector Keun (Reader in metabolic biochemistry, Imperial College London, Department of Surgery and Cancer)
14.30 – 15.00 Coffee break, posters and exhibitors
15.00 – 16.30 Parallel workshop: The future of translational science in early stage oncology trials: How will the ECMC network continue to deliver high quality biomarker research?
What are the current challenging areas of drug discovery in need of biomarker solutions? How might we address these challenges?
How will the role of translational science in clinical trials evolve in the future? Strategies for managing multiple markers and tests for precision treatment of cancer?
How will the ECMC network deliver these future needs?
15.00 – 16.30 Parallel workshop: Challenges for translational science analytical validation in early phase oncology trials
In your ECMC, do you apply the same QA across all assays, irrespective of whether they are primary endpoint or not?
Should primary, secondary, or tertiary endpoints have the same or differing quality assurance requirements? Why? What are benefits/drawbacks?
What are the challenges in implementation of assay validation to complex or novel translational science techniques? Can the ECMC network be leveraged to help to address these challenges? If so, how?
16.30 – 17.30 Panel discussion
Featuring selected speakers from the day and QATS committee members
Please note non-ECMC, non-academic members there is a fee of £25 to cover expenses for the day. The fee can be paid by cheque made payable to The Institute of Cancer Research, bank transfer or can be invoiced. Cheques can be mailed to Dr Karen Swales at The Institute of Cancer Research, Division of Cancer Therapeutics, 15 Cotswold Road. Sutton, Surrey, SM2 5NG. To request bank transfer details or an invoice please email Karen.Swales@icr.ac.uk. Please include your full name, if you are Non ECMC / Academic or
Non-ECMC / Non-academic, and conference registration order number in any correspondence.
Travel and Accommodation
Please contact email@example.com if you require any help with travel and accommodation, as there may be some financial support available.
Please also note that there is limited on-site parking.
Access/ Mobility requirements
If you have specific access requirements or are mobility impaired, please email Karen.Swales@icr.ac.uk
For general enquiries please contact firstname.lastname@example.org